Regarding the safety of sGC stimulators use in HF patients, when compared with a placebo, sGC stimulators were safe and well-tolerable with no reported serious adverse events, adverse events leading to drug discontinuation, or any adverse events, including syncope and AKI. This evidence concerns the gene SGCB and acute kidney injury.